Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach (original) (raw)

Cancer Gene Therapy volume 8, pages 45–54 (2001)Cite this article

Abstract

Based on the observation that the growth of solid tumors is dependent on the formation of new blood vessels, therapeutic strategies aimed at inhibiting angiogenesis have been proposed. A number of proteins with angiostatic activity have been described, but their development as therapeutic agents has been hampered by difficulties in their production and their poor pharmacokinetics. These limitations may be resolved using a gene therapy approach whereby the genes are delivered and expressed in vivo. Here we compared adenoviral delivery of endostatin, proliferin-related protein (PRP), and interferon-inducible protein 10 (IP10) genes. Recombinant adenoviruses carrying the three angiostatic genes express biologically active gene products as determined in vitro in endothelial cell proliferation and migration assays, and in vivo by inhibition of neoangiogenesis in rat chambers. Eradication of established tumors in vivo, in the murine B16F10 melanoma model in immunocompetent mice, was not achieved by intratumoral injection of the different vectors. However, the combination of intravenous plus intratumoral injections allowed rejection of tumors. Ad-PRP or Ad-IP10 were significantly more efficient than Ad-endostatin, leading to complete tumor rejection and prolonged survival in a high proportion of treated animals. These data support the use of in vivo gene delivery approaches to produce high-circulating and local levels of antiangiogenic agents for the therapy of local and metastatic human tumors. Cancer Gene Therapy (2001) 8, 45–54

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Author information

Authors and Affiliations

  1. TRANSGENE, Strasbourg, 67082, France
    Etienne Régulier, Stéphane Paul, Martine Marigliano, Jacqueline Kintz, Yves Poitevin, Catherine Ledoux, Dominique Roecklin, Gilles Cauet, Valérie Calenda & Horst E. Homann

Authors

  1. Etienne Régulier
    You can also search for this author inPubMed Google Scholar
  2. Stéphane Paul
    You can also search for this author inPubMed Google Scholar
  3. Martine Marigliano
    You can also search for this author inPubMed Google Scholar
  4. Jacqueline Kintz
    You can also search for this author inPubMed Google Scholar
  5. Yves Poitevin
    You can also search for this author inPubMed Google Scholar
  6. Catherine Ledoux
    You can also search for this author inPubMed Google Scholar
  7. Dominique Roecklin
    You can also search for this author inPubMed Google Scholar
  8. Gilles Cauet
    You can also search for this author inPubMed Google Scholar
  9. Valérie Calenda
    You can also search for this author inPubMed Google Scholar
  10. Horst E. Homann
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toHorst E. Homann.

Rights and permissions

About this article

Cite this article

Régulier, E., Paul, S., Marigliano, M. et al. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach.Cancer Gene Ther 8, 45–54 (2001). https://doi.org/10.1038/sj.cgt.7700278

Download citation

Keywords